Company plans to use these funds for various purposes, including capex, overseas acquisitions and joint ventures.
In October, Wanbury had planned to acquire the generics business of Spain's Industrial Farmaceutica Cantabria for 42 million euros in addition to potential milestone payments of 8 million euros.